Together, we can fill knowledge gaps about low-grade glioma brain tumors, allowing us to guide future treatments.
What is the study about?

Little is known about low grade glioma (LGG), a slow growing brain tumor. To learn more about gliomas, we are asking adults diagnosed with LGG to join this study to discover why some people develop glioma while other people do not.

Who can join the registry?

The Registry recruits people to participate from across the globe, via social media and at a number of different hospitals, including Dana Farber Cancer Institute and Yale New Haven Hospital.

1. Must be currently between ages 21-79 (regardless of age at diagnosis)
2. Must have a confirmed pathology for grade 2 or 3 glioma (via surgery)
3. No restrictions based on sex, gender, race/ethnicity, or geography. However, OPTIMUM participants must receive their care in the US.
4. Those with recurrent LGG (2+ surgeries) may be eligible for OPTIMUM, a study within the registry

What to expect

- Complete a consent form
- Share your health information via secure health server (Hugo Health)
- Complete a questionnaire (30 min)
- Provide samples (i.e., saliva or blood spot) via mail
- Sample genes will be analyzed
- Genetic analysis results returned (OPTIMUM only). You may discuss these with your provider.

Participation in the Low-Grade Glioma Registry involves a few steps:

With your permission, we access tumor samples from prior surgeries to study these tumors as well.

You may opt out of the study at any point. Your information will be stored confidentially. Please refer to our consent form for further details.